Duchesnay Inc.

22 articles with Duchesnay Inc.

• Duchesnay announces the launch of Vablys® (dequalinium chloride vaginal tablets), an antiseptic and anti-infective treatment for bacterial vaginosis

  6/21/2022

  Duchesnay Inc, a pharmaceutical company specializing in women’s health and part of Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec, is pleased to announce that it has launched its newest treatment, Vablys ® (dequalinium chloride vaginal tablets).

• Slynd® (drospirenone), a new progestin-only contraceptive pill from Duchesnay which offers a 24-hour safe window for a missed pill

  5/17/2022

  A new progestin-only contraceptive pill is now available to Canadians from Duchesnay Inc., a pharmaceutical company specializing in women’s health and part of the Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec.

• Postmenopausal Canadian women experiencing vaginal dryness and painful intercourse have a new oral once-daily prescription treatment, Osphena® (ospemifene tablets) from Duchesnay

  2/14/2022

  Duchesnay Inc., a pharmaceutical company specializing in women's health and part of the Duchesnay Pharmaceutical Group based in Blainville, Quebec, is proud to announce the first treatment launched by its new ownership and management team to help postmenopausal women across Canada who are suffering from vaginal dryness and painful intercourse.

• Duchesnay USA and FabOverFifty launch Straight Talk: Sex and the Menopausal Woman video

  6/4/2020

  ROSEMONT, PA, June 4, 2020 /PRNewswire/ - Duchesnay USA, a pharmaceutical company that specializes in women's health, is proud to announce the launch of a new video titled Straight Talk: Sex and the Menopausal Woman.

• Duchesnay USA and Plushcare announce a new partnership to facilitate access to healthcare for menopausal women through telemedicine

  5/19/2020

  Duchesnay USA, a pharmaceutical company dedicated to women's health, and PlushCare, a virtual health platform are announcing that women who are experiencing menopause symptoms can now request a virtual appointment with an independent healthcare provider via the PlushCare platform through osphena.com.

• Duchesnay USA launches three videos featuring gynecologist and menopause care specialist, Dr. Barb DePree

  8/20/2019

  Duchesnay USA, a pharmaceutical company that specializes in women's health, is pleased to announce the launch of three new videos featuring gynecologist and menopause care specialist, Dr. Barb DePree.

• Effects of Ospemifene on Genitourinary Health: Prospective Vulvar-Vestibular Photography and Direct Assessments in Post-Menopausal Women

  6/5/2019

  Duchesnay Inc., a pharmaceutical company specializing in women's health, is pleased to announce the publication of a study showing improvements in vulvovaginal health with ospemifene as assessed by prospective vulvar-vestibular photography and other direct visual assessments.

• Duchesnay USA Pledges Continued Support of the Mobile Mom Squad through Donations of its Mteryti and Mteryti folic 5 Prenatal Supplements

  3/5/2019

  The Mobile Mom Squad assists women in need in the US, as well as in several developing countries.

• Duchesnay Inc. Receives Approval of Supplemental New Drug Application (sNDA) to Add Moderate to Severe Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause, to the Indication of Osphena® (ospemifene)

  1/29/2019

  Duchesnay Inc. announced today that the FDA has approved its supplemental New Drug Application (sNDA) seeking to add moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy (VVA), due to menopause, to the indication of Osphena® (ospemifene).

• Duchesnay USA, Maker of Osphena, Applauds Expanded Coverage for Treatments for Dyspareunia due to Menopause under Medicare Part D

  10/29/2018

  Duchesnay USA commends the clarification by the Centers for Medicare and Medicaid Services (CMS) of the statutory intent of "Prescription Drug Benefits" Section 1860D-2(e)(2)(A) of the Social Security Act.

• Duchesnay Inc. Announces Submission of Supplemental New Drug Application (sNDA) for Osphena (ospemifene) to U.S. FDA Seeking Approval for the Treatment of Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause

  10/23/2018

   Duchesnay Inc., a pharmaceutical company specializing in women's health, announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) seeking a new indication for Osphena® (ospemifene).

• Duchesnay USA Continues the Morning Sickness Conversation with Actress, Mom and Singer Jana Kramer and Beverly Hills Ob/Gyn Dr. Jay Goldberg

  10/16/2018

  Celebrity and her doctor join forces to stress the importance of communication between patients and healthcare providers

• Duchesnay Inc. to Present a Poster on Adherence, Persistence and Healthcare Costs Associated with Ospemifene at 2018 Annual Meeting of the North American Menopause Society (NAMS)

  9/14/2018

  Duchesnay Inc. announced today that it will present a poster on the topic of ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS) in San Diego.

• Duchesnay Inc. to Present a Poster on Ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS)

  9/13/2018

  Duchesnay Inc. announced today that it will present a poster on the topic of ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS) in San Diego.

• Duchesnay Inc. to Present a Poster on the Efficacy and Safety of Ospemifene in Menopausal Women with Moderate to Severe Vaginal Dryness at 2018 Annual Meeting of the North American Menopause Society (NAMS)

  9/12/2018

  Duchesnay Inc. announced today that it will present a poster on the topic of ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS) in San Diego.

• Mictoryl® Pediatric (propiverine hydrochloride) now covered by several public drug plans to treat symptoms associated with overactive bladder

  6/7/2018

  Indicated for the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in pediatric patients, from the age of 5 years, with overactive bladder.

• Menopausal Women Staying Silent About Painful Sex - Recent Survey Highlights Knowledge Gap About Treatment Options

  5/30/2018

  HealthyWomen along with Duchesnay USA announced the results of a survey* evaluating the experience of postmenopausal women with one of the most common and troubling symptoms of menopause: painful sex.

• Duchesnay USA Announces Launch of Bonjesta® in the United States

  4/2/2018

  Bonjesta is indicated for the treatment of nausea and vomiting of pregnancy ("NVP") in women who do not respond to conservative management.

• Mictoryl And Mictoryl Pediatric Now Available And Distributed In Canada By Duchesnay

  5/9/2017

• Duchesnay Expands Its Women's Health Product Portfolio With Acquisition Of Osphena From Shionogi

  3/13/2017